Cargando…
Efficacy of a Novel Pleiotropic MMP-Inhibitor, CMC2.24, in a Long-Term Diabetes Rat Model with Severe Hyperglycemia-Induced Oral Bone Loss
PURPOSE: CMC2.24, a novel 4-(phenylaminocarbonyl)-chemically-modified-curcumin, is a pleiotropic MMP-Inhibitor of various inflammatory/collagenolytic diseases including periodontitis. This compound has demonstrated efficacy in host modulation therapy along with improved resolution of inflammation in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969803/ https://www.ncbi.nlm.nih.gov/pubmed/36860795 http://dx.doi.org/10.2147/JIR.S399043 |
_version_ | 1784897801148170240 |
---|---|
author | Bhatt, Heta Dinesh Golub, Lorne M Lee, Hsi-Ming Kim, Jihwan Zimmerman, Thomas Deng, Jie Hong, Houlin Johnson, Francis Gu, Ying |
author_facet | Bhatt, Heta Dinesh Golub, Lorne M Lee, Hsi-Ming Kim, Jihwan Zimmerman, Thomas Deng, Jie Hong, Houlin Johnson, Francis Gu, Ying |
author_sort | Bhatt, Heta Dinesh |
collection | PubMed |
description | PURPOSE: CMC2.24, a novel 4-(phenylaminocarbonyl)-chemically-modified-curcumin, is a pleiotropic MMP-Inhibitor of various inflammatory/collagenolytic diseases including periodontitis. This compound has demonstrated efficacy in host modulation therapy along with improved resolution of inflammation in various study models. The objective of current study is to determine the efficacy of CMC2.24 in reducing the severity of diabetes, and its long-term role as an MMP-inhibitor, in a rat model. METHODS: Twenty-one adult male Sprague-Dawley rats were randomly distributed into three groups: Normal (N), Diabetic (D) and Diabetic+CMC2.24 (D+2.24). All three groups were orally administered vehicle: carboxymethylcellulose alone (N, D), or CMC2.24 (D+2.24; 30mg/kg/day). Blood was collected at 2-months and 4-months’ time-point. At completion, gingival tissue and peritoneal washes were collected/analyzed, and jaws examined for alveolar bone loss by micro-CT. Additionally, sodium hypochlorite(NaClO)-activation of human-recombinant (rh) MMP-9 and its inhibition by treatment with 10μM CMC2.24, Doxycycline, and Curcumin were evaluated. RESULTS: CMC2.24 significantly reduced the levels of lower-molecular-weight active-MMP-9 in plasma. Similar trend of reduced active-MMP-9 was also observed in cell-free peritoneal and pooled gingival extracts. Thus, treatment substantially decreased conversion of pro- to actively destructive proteinase. Normalization of the pro-inflammatory cytokine (IL-1ß, resolvin-RvD1), and diabetes-induced osteoporosis was observed in presence of CMCM2.24. CMC2.24 also exhibited significant anti-oxidant activity by inhibiting the activation of MMP-9 to a lower-molecular-weight (82kDa) pathologically active form. All these systemic and local effects were observed in the absence of reduction in severity of hyperglycemia. CONCLUSION: CMC2.24 reduced activation of pathologic active-MMP-9, normalized diabetic osteoporosis, and promoted resolution of inflammation but had no effect on the hyperglycemia in diabetic rats. This study also highlights the role of MMP-9 as an early/sensitive biomarker in the absence of change in any other biochemical parameter. CMC2.24 also inhibited significant activation of pro-MMP-9 by NaOCl (oxidant) adding to known mechanisms by which this compound treats collagenolytic/inflammatory diseases including periodontitis. |
format | Online Article Text |
id | pubmed-9969803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-99698032023-02-28 Efficacy of a Novel Pleiotropic MMP-Inhibitor, CMC2.24, in a Long-Term Diabetes Rat Model with Severe Hyperglycemia-Induced Oral Bone Loss Bhatt, Heta Dinesh Golub, Lorne M Lee, Hsi-Ming Kim, Jihwan Zimmerman, Thomas Deng, Jie Hong, Houlin Johnson, Francis Gu, Ying J Inflamm Res Original Research PURPOSE: CMC2.24, a novel 4-(phenylaminocarbonyl)-chemically-modified-curcumin, is a pleiotropic MMP-Inhibitor of various inflammatory/collagenolytic diseases including periodontitis. This compound has demonstrated efficacy in host modulation therapy along with improved resolution of inflammation in various study models. The objective of current study is to determine the efficacy of CMC2.24 in reducing the severity of diabetes, and its long-term role as an MMP-inhibitor, in a rat model. METHODS: Twenty-one adult male Sprague-Dawley rats were randomly distributed into three groups: Normal (N), Diabetic (D) and Diabetic+CMC2.24 (D+2.24). All three groups were orally administered vehicle: carboxymethylcellulose alone (N, D), or CMC2.24 (D+2.24; 30mg/kg/day). Blood was collected at 2-months and 4-months’ time-point. At completion, gingival tissue and peritoneal washes were collected/analyzed, and jaws examined for alveolar bone loss by micro-CT. Additionally, sodium hypochlorite(NaClO)-activation of human-recombinant (rh) MMP-9 and its inhibition by treatment with 10μM CMC2.24, Doxycycline, and Curcumin were evaluated. RESULTS: CMC2.24 significantly reduced the levels of lower-molecular-weight active-MMP-9 in plasma. Similar trend of reduced active-MMP-9 was also observed in cell-free peritoneal and pooled gingival extracts. Thus, treatment substantially decreased conversion of pro- to actively destructive proteinase. Normalization of the pro-inflammatory cytokine (IL-1ß, resolvin-RvD1), and diabetes-induced osteoporosis was observed in presence of CMCM2.24. CMC2.24 also exhibited significant anti-oxidant activity by inhibiting the activation of MMP-9 to a lower-molecular-weight (82kDa) pathologically active form. All these systemic and local effects were observed in the absence of reduction in severity of hyperglycemia. CONCLUSION: CMC2.24 reduced activation of pathologic active-MMP-9, normalized diabetic osteoporosis, and promoted resolution of inflammation but had no effect on the hyperglycemia in diabetic rats. This study also highlights the role of MMP-9 as an early/sensitive biomarker in the absence of change in any other biochemical parameter. CMC2.24 also inhibited significant activation of pro-MMP-9 by NaOCl (oxidant) adding to known mechanisms by which this compound treats collagenolytic/inflammatory diseases including periodontitis. Dove 2023-02-23 /pmc/articles/PMC9969803/ /pubmed/36860795 http://dx.doi.org/10.2147/JIR.S399043 Text en © 2023 Bhatt et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Bhatt, Heta Dinesh Golub, Lorne M Lee, Hsi-Ming Kim, Jihwan Zimmerman, Thomas Deng, Jie Hong, Houlin Johnson, Francis Gu, Ying Efficacy of a Novel Pleiotropic MMP-Inhibitor, CMC2.24, in a Long-Term Diabetes Rat Model with Severe Hyperglycemia-Induced Oral Bone Loss |
title | Efficacy of a Novel Pleiotropic MMP-Inhibitor, CMC2.24, in a Long-Term Diabetes Rat Model with Severe Hyperglycemia-Induced Oral Bone Loss |
title_full | Efficacy of a Novel Pleiotropic MMP-Inhibitor, CMC2.24, in a Long-Term Diabetes Rat Model with Severe Hyperglycemia-Induced Oral Bone Loss |
title_fullStr | Efficacy of a Novel Pleiotropic MMP-Inhibitor, CMC2.24, in a Long-Term Diabetes Rat Model with Severe Hyperglycemia-Induced Oral Bone Loss |
title_full_unstemmed | Efficacy of a Novel Pleiotropic MMP-Inhibitor, CMC2.24, in a Long-Term Diabetes Rat Model with Severe Hyperglycemia-Induced Oral Bone Loss |
title_short | Efficacy of a Novel Pleiotropic MMP-Inhibitor, CMC2.24, in a Long-Term Diabetes Rat Model with Severe Hyperglycemia-Induced Oral Bone Loss |
title_sort | efficacy of a novel pleiotropic mmp-inhibitor, cmc2.24, in a long-term diabetes rat model with severe hyperglycemia-induced oral bone loss |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969803/ https://www.ncbi.nlm.nih.gov/pubmed/36860795 http://dx.doi.org/10.2147/JIR.S399043 |
work_keys_str_mv | AT bhatthetadinesh efficacyofanovelpleiotropicmmpinhibitorcmc224inalongtermdiabetesratmodelwithseverehyperglycemiainducedoralboneloss AT golublornem efficacyofanovelpleiotropicmmpinhibitorcmc224inalongtermdiabetesratmodelwithseverehyperglycemiainducedoralboneloss AT leehsiming efficacyofanovelpleiotropicmmpinhibitorcmc224inalongtermdiabetesratmodelwithseverehyperglycemiainducedoralboneloss AT kimjihwan efficacyofanovelpleiotropicmmpinhibitorcmc224inalongtermdiabetesratmodelwithseverehyperglycemiainducedoralboneloss AT zimmermanthomas efficacyofanovelpleiotropicmmpinhibitorcmc224inalongtermdiabetesratmodelwithseverehyperglycemiainducedoralboneloss AT dengjie efficacyofanovelpleiotropicmmpinhibitorcmc224inalongtermdiabetesratmodelwithseverehyperglycemiainducedoralboneloss AT honghoulin efficacyofanovelpleiotropicmmpinhibitorcmc224inalongtermdiabetesratmodelwithseverehyperglycemiainducedoralboneloss AT johnsonfrancis efficacyofanovelpleiotropicmmpinhibitorcmc224inalongtermdiabetesratmodelwithseverehyperglycemiainducedoralboneloss AT guying efficacyofanovelpleiotropicmmpinhibitorcmc224inalongtermdiabetesratmodelwithseverehyperglycemiainducedoralboneloss |